Contact
      Please use this form to send email to PR contact of this press release:
      
      Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014
    
      TO: